HOME > News > Press Releases > 2023.6.21 Glac Biotech’s International Probiotic Ingredients Make Their Mark in Europe and the U.S.
2023.6.21 Glac Biotech’s International Probiotic Ingredients Make Their Mark in Europe and the U.S.
At first glance, it might seem like Glac Biotech’s global success story happened overnight. Today, its probiotics and postbiotic innovations are recognized across five continents — in the U.K., U.S., Australia, South Korea, and Southeast Asia. But behind this rise is a journey of reinvention, persistence, and science-driven ambition.
With its proprietary PRONEX® technology, Glac Biotech has redefined probiotic quality — optimizing bacterial vitality and pairing it with robust clinical validation. The result is a portfolio of natural, science-backed products that international brands trust. Global demand has followed, and in recent years, Glac has opened a new chapter in international probiotic supply.
From Early Challenges to Global Recognition
The path was not without obstacles. In its early years, Glac’s factories lacked the full certifications required to compete with global giants. But instead of retreating, the company chose transformation. Beginning last year, Glac reset its strategy, benchmarking itself against leading international players.
The shift was bold:
Expanding on the Global Stage
As demand for natural health products accelerates worldwide, Glac is intensifying its international presence. The company has ramped up its exhibition strategy:
Vitafoods Europe (Geneva), the continent’s largest nutrition trade show, on the calendar for the first half of the year.
A slate of exhibitions in Europe, North America, and Asia in the second half, where Glac will showcase its newest probiotic and postbiotic solutions, all validated by human clinical studies.
These initiatives are more than promotion — they are opportunities to deepen partnerships and build long-term relationships with global leaders in health and nutrition.
Totipro® Postbiotics: A Breakthrough Brand
At the heart of Glac’s innovation lies Totipro®, its next-generation postbiotic line. Built on patented processes and validated by human evidence, Totipro® products have earned 13 international patents for their efficacy.
Among them, Totipro® PE0401 has already achieved strong sales in Europe and the U.S., demonstrating how Glac’s science translates into real-world success.
Raising Taiwan’s Profile on the Global Stage
Glac Biotech is proving that probiotics and postbiotics from Taiwan can stand tall on the international market. By delivering safe, high-quality, and scientifically validated raw materials, the company is polishing its reputation abroad and strengthening Taiwan’s role as a leader in natural health innovation.
Looking forward, Glac is determined to keep expanding partnerships, fueling the global probiotic market, and working hand-in-hand with international companies to healthier, better lives worldwide.
With its proprietary PRONEX® technology, Glac Biotech has redefined probiotic quality — optimizing bacterial vitality and pairing it with robust clinical validation. The result is a portfolio of natural, science-backed products that international brands trust. Global demand has followed, and in recent years, Glac has opened a new chapter in international probiotic supply.
From Early Challenges to Global Recognition
The path was not without obstacles. In its early years, Glac’s factories lacked the full certifications required to compete with global giants. But instead of retreating, the company chose transformation. Beginning last year, Glac reset its strategy, benchmarking itself against leading international players.
The shift was bold:
- Launching multiple clinical studies on functional probiotics.
- Partnering with Nordic equipment specialists to co-develop advanced manufacturing systems.
- Securing internationally recognized certifications for its production facilities.
Expanding on the Global Stage
As demand for natural health products accelerates worldwide, Glac is intensifying its international presence. The company has ramped up its exhibition strategy:
Vitafoods Europe (Geneva), the continent’s largest nutrition trade show, on the calendar for the first half of the year.
A slate of exhibitions in Europe, North America, and Asia in the second half, where Glac will showcase its newest probiotic and postbiotic solutions, all validated by human clinical studies.
These initiatives are more than promotion — they are opportunities to deepen partnerships and build long-term relationships with global leaders in health and nutrition.
Totipro® Postbiotics: A Breakthrough Brand
At the heart of Glac’s innovation lies Totipro®, its next-generation postbiotic line. Built on patented processes and validated by human evidence, Totipro® products have earned 13 international patents for their efficacy.
Among them, Totipro® PE0401 has already achieved strong sales in Europe and the U.S., demonstrating how Glac’s science translates into real-world success.
Raising Taiwan’s Profile on the Global Stage
Glac Biotech is proving that probiotics and postbiotics from Taiwan can stand tall on the international market. By delivering safe, high-quality, and scientifically validated raw materials, the company is polishing its reputation abroad and strengthening Taiwan’s role as a leader in natural health innovation.
Looking forward, Glac is determined to keep expanding partnerships, fueling the global probiotic market, and working hand-in-hand with international companies to healthier, better lives worldwide.
Media Coverage
Commercial Times — Jun 21, 2023 (Chinese)
豐華生技國際布局成果顯著，益生菌與後生元進軍歐美市場
-
2024.5.31 Glac Biotech’s Probiotic Business Set to Break NT$500 Million in Revenue — A Story of Growth, Strategy, and Gl
-
2023.11.24 Glac Biotech’s Totipro® PE0401 Wins Global Recognition at the NutraIngredients Awards
-
2023.9.28 Glac Biotech’s Totipro® PE0401 Makes History — First Postbiotic Ever to Win a NutraIngredients Award
-
2024.7.23 Glac Biotech Unveils Next-Generation Probiotic Technology and Brain Health Innovations